Cumberland Pharmaceuticals Reports Q4 Loss of $0.05/sh
Cumberland Pharmaceuticals (NASDAQ:CPIX) reported Q4 EPS of ($0.05). Revenue for the quarter came in at $9.1 million versus the consensus estimate of $8.07 million.
-
-
: Realty Income inks $1.5 bln sale leaseback deal for Cumberland Farms and other stores
Realty Income Corp. O said Monday it reached a $1.5 billion sale leaseback deal to acquire up to 415 single-tenant convenience store properties located in the U.S. from EG Group, a...
-
Institutional DeFi Startup Hashnote Is First to Emerge From Incubator Cumberland Labs
The regulated DeFi asset manager was launched with a $5 million investment from the Web3 incubator.
-
Cumberland Pharmaceuticals Tops Q1 EPS by 3c
Cumberland Pharmaceuticals (NASDAQ:CPIX) reported Q1 EPS of $0.03, $0.03 better than the analyst estimate of $0.00. Revenue for the quarter came in at $11.2 million versus the consensus...
-
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.87%
Investing.com – U.S. equities were higher at the close on Monday, as gains in the Consumer Services, Utilities and Basic Materials sectors propelled shares higher. At the close in NYSE, the...
-
U.S. shares lower at close of trade; Dow Jones Industrial Average down 1.86%
Investing.com – U.S. equities were lower at the close on Tuesday, as losses in the Telecoms, Utilities and Basic Materials sectors propelled shares lower. At the close in NYSE, the Dow...
-
Cumberland Pharmaceuticals Stock Rockets After FDA Approves Labeling
By Sam Boughedda Investing.com — Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) Shares have more than doubled Tuesday after the U.S. Food and Drug Administration approved expanded labeling for...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
